Gynaecology Flashcards

1
Q

What causes gonads to develop into testis?

A
  • SRY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the development of the male sexual organs

A
  • As the gonads become testes, it differentiates into TWO cell types:
    • Sertoli cells - produce anti-Mullerian hormone (AMH)
    • Leydig cells - produce testosterone
  • AMH suppresses further development of the Mullerian ducts
  • Testosterone stimulates the Wolffian ducts to develop into the vas deferens, epididymis and seminal vesicles
  • Testosterone is converted to DHT by 5a-reductase in the external genital skin to virilise the external genitalia
  • The genital tubercle becomes the penis and the labioscrotal folds fuse to form the scrotum
  • The urogenital folds fuse along the ventral surface of the penis and enclose the urethra
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the development of the female sexual organs

A
  • In the primitive ovary, granulosa cells surround the germ cells and form primordial follicles
  • Each follicle consists of an oocyte within a single layer of granulosa cells
  • Thecal cells develop from the proliferating coelomic epithelium and are separated from granulosa cells by basal lamina
  • The maximum number of primordial follicles are reached at 20 weeks (roughly 6-7 million)
  • The numbers reduce by atresia and by birth only 1-2 million remain
  • Atresia continues throughout life and about 300,000-400,000 are present at menarche
  • The development of an oocyte within the primordial follicle is arrested in prophase of its first meiotic division
  • It remains like this until it either undergoes atresia or enters the meiotic process preceding ovulation
  • The absence of AMH in the female allows development of the Mullerian structures
  • The proximal 2/3 of the vagina develop from the paired Mullerian ducts
  • The midline fusion of these structures produces the uterus, cervix and upper vagina
  • The unfused caudal segments form the Fallopian tubes
  • Cells from the upper part of the urogenital sinus proliferate to produce the sinovaginal bulbs
  • The caudal extension of the Mullerian ducts projects into the posterior wall of the urogenital sinus as the Mullerian tubercle
  • The Mullerian ducts and the urogenital sinus fuse and canalise starting at the hymen and moving up to the cervix
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do the external female genitalia develop?

A
  • Do NOT virilise in the absence of testosterone
  • Cloacal folds fuse anteriorly to become the genital tubercle (this becomes the clitoris)
  • The cloacal folds anteriorly are called the urethral folds and form the labia minora
  • Another pair of folds within the cloacal membrane form the labioscrotal folds which form the labia majora
  • The urogenital sinus becomes the vestibule of the vagina
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What does the vulva (external genitalia) include?

A
  • Mons pubis
  • Labia majora
  • Labia minora
  • Vaginal vestibule
  • Clitoris
  • Greater vestibular glands
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the labia majora and minora

A
  • The labia majora contain sebaceous and sweat glands
  • There is a core of fatty tissue at the deepest part of each labium
  • The labia minora divide anteriorly to form the prepuce and frenulum of the clitoris (clitoral hood)
  • Posteriorly they divide to form the fourchette
  • The labia minora contain sebaceous glands but no adipose tissue
  • Both labia become engorged during sexual arousal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the clitoris?

A
  • The clitoris is made up of paired columns of erectile and vascular tissue called the corpora cavernosa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the vestibule?

A
  • The vestibule is the cleft between the labia minora

- It contains openings of the urethra, Bartholin’s glands and the vagina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the Bartholin’s glands?

A
  • They are bilateral and about the size of a pea

- They open via a 2 cm duct into the vestibule below the hymen and contribute to lubrication during intercourse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the hymen?

A
  • The hymen is a thin covering mucous membrane across the entrance to the vagina
  • It is usually perforated to allow menstruation
  • It is ruptured during intercourse
  • Any remaining tags are called carunculae myrtiformes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the vagina

A
  • The vagina is a fibromuscular canal lines by stratified squamous epithelium
  • It is longer in the posterior wall (9 cm) than the anterior wall (7 cm)
  • The vault of the vagina is divided into FOUR fornices: posterior, anterior and two lateral
    • NOTE: the vault is the expanded region of the vaginal canal at the internal end of the vagina
  • The vaginal wall is lined by transverse folds
  • The vagina has NO glands and is kept moist by secretions from the uterine and cervical glands and by transudation from the epithelial lining
  • The epithelium is thick and rich in glycogen
  • Before puberty and after menopause, the vagina has NO glycogen because of a lack of stimulation by oestrogen
  • Doderlein’s bacillus is a normal commensal that breaks down glycogen to form lactic acid producing a low pH (this is protective as it prevents the growth of pathogenic bacteria)
  • Anteriorly the vagina is in direct contact with the base of the bladder
  • Laterally, at the fornices, the vagina is related to the cardinal ligaments
  • Below this you see the levator ani muscles and ischiorectal fossae
  • The cardinal ligaments and uterosacral ligaments form the parametrium
  • At birth, the vagina is under the influence of maternal oestrogens so is well developed
  • After a few weeks after birth, these effects will disappear
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the Uterus

A
  • Maximum external dimensions = 7.5 cm x 5 cm x 3 cm
  • Adult uterus weight = 70 g
  • The cornu is the site of insertion of the Fallopian tube
  • The corpus is the body of the uterus
  • The area of the uterus above the cornu is the fundus
  • The longitudinal axis of the uterus is roughly at right angles to the vagina and tilts forwards (anteversion)
  • The uterus also flexes forwards on itself (anteflexion)
  • In 20% of women, the uterus is tilted backwards (retroversion and retroflexion)
  • This is of NO pathological significance
  • The os is the opening of the cervix
  • The internal os is where the mucous membrane of the isthmus becomes that of the cervix
  • The uterus has THREE layers:
    • Peritoneum - outer serous layer
    • Myometrium - middle muscular layer
    • Endometrium - inner mucous layer
  • The peritoneum covers the body of the cervix and the supravaginal part of the cervix
  • The peritoneum is attached to the subserous fibrous layer, except laterally where it spreads out to form the leaves of the broad ligament
  • Externally, the myometrium consists of mostly longitudinal muscle fibres
  • The thicker intermediate layer has interlacing longitudinal, oblique and transverse fibres
  • Internally, they are mainly longitudinal and circular
  • The inner endometrial layer has tubular glands that dip into the myometrium
  • The endometrial layer is covered by a single layer of columnar epithelium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the Cervix

A
  • Roughly 2.5 cm in length
  • Lateral to the cervix is the parametrium (connective tissue)
  • The ureters run 1 cm laterally to the supravaginal part of the cervix
  • The mucous membrane of the cervix (endocervix) has anterior and posterior columns from which folds radiate out (arbour vitae)
  • It has lots of deep glandular follicles that secrete clear alkaline mucus (the main component of physiological vaginal discharge)
  • The epithelium of the endocervix is columnar and ciliated in the upper 2/3
  • This will transition to squamous epithelium at the squamocolumnar junction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What age related changes happen to the anatomy of the female sexual organs?

A
  • Loss of maternal oestrogens from the circulation after birth causes the uterus to decrease in length and weight
  • The cervix will be twice the length of the uterus at this point
  • During childhood, the uterus grows slowly
  • After the onset of puberty, the dimensions of the uterus start to increase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the fallopian tubes

A
  • Extend outwards from the uterine cornu to end near the ovary
  • At the abdominal ostium, the tube opens into the peritoneal cavity
  • The Fallopian tubes take the ovum from the ovary towards the uterus and promote oxygenation and nutrition for sperm, ovum and zygote
  • They run in the upper margin of the broad ligament (mesosalpinx)
  • This encloses the tube so that it is completely covered by peritoneum (except for a thin strip on the inferior side)
  • Each tube is roughly 10 cm long and has FOUR parts:
    • Interstitial portion (lies within the wall of the uterus)
    • Isthmus (narrow portion adjoining the uterus)
    • Ampulla (widest and longest part)
    • Infundibulum or fimbrial portion (opening of the tube into the peritoneal cavity)
  • One of the fimbriae extend and partially embrace the ovary
  • The muscular wall of the tube has an inner circular and an outer longitudinal layer
  • The tube epithelium forms a number of folds or plicae that run longitudinally
  • There is NO submucosa and NO glands
  • The epithelium has TWO cell types:
    • Ciliated cells (produce a constant current of fluid in the direction of the uterus)
    • Secretory cells (contribute to the volume of tubal fluid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the Ovaries

A
  • Size and appearance depends on age and stage of the menstrual cycle
  • Proliferation of stromal cells in puberty makes them grow in size (reaching 3 cm long x 1.5 cm wide x 1 cm thick)
  • The ovary becomes smaller after menopause
  • The ovary is the only intra-abdominal structure that is NOT covered by peritoneum
  • Each ovary is attached to the cornu of the uterus by the ovarian ligament
  • It is also attached to the broad ligament by the mesovarium, which contains nerves and blood vessels
  • Laterally, each ovary is attached to the suspensory ligament of the ovary with folds of peritoneum that become continuous with the overlying psoas major
  • Anterior to the ovaries are the Fallopian tubes, superior portion of the bladder and the uterovesical pouch
  • Posterior to the ovary is the ureter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the structure of the ovaries

A
  • It has a central vascular medulla consisting of loose connective tissue containing elastin fibres and non-striated muscle cells
  • It has an outer thicker cortex which is denser than the medulla
  • It contains networks of reticular fibres and fusiform cells
  • The surface of the ovaries has a single layer of cuboidal cells (germinal epithelium)
  • Underneath this layer is another layer called the tunica albuginea (increases in density with age)
  • At birth, most primordial follicles are found within the cortex
  • After puberty, some follicles become Graafian follicles and ovulate and become the corpus luteum
  • This will ultimately undergo atresia and become the corpora albicans
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe the bladder

A
  • The bladder is made of involuntary muscle arranged in an inner longitudinal layer, middle circular layer and outer longitudinal layer
  • It is lined by transitional epithelium
  • The average capacity is 400 mL
  • The ureters open into the base of the bladder after running through the bladder wall for about 1 cm
  • The internal meatus of the urethra is known as the trigone
  • The base of the bladder is adjacent to the cervix
  • It is separated from the anterior vaginal wall by pubocervical fascia that stretches from the pubis to the cervix
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the urethra

A
  • Roughly 3.5 cm long
  • Lined with transitional epithelium
  • Smooth muscle of the wall is arranged into outer longitudinal and inner circular layers
  • The upper part of the urethra is mobile but the lower part is relatively fixed
  • On voluntary voiding of urine, the base of the bladder and the upper part of the urethra descend and the posterior angle disappears so that the base of the bladder and the posterior wall of the urethra come to lie in a straight line
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Describe the ureter

A
  • As the ureter crosses the pelvic brim, it lies in front of the bifurcation of the common iliac artery
  • It reaches the pelvic floor and then passes inwards and forwards to attach to the peritoneum of the back of the broad ligament, passing under the uterine artery
  • It then passes through the ureteric canal
  • It runs close to the lateral vaginal fornix to enter the trigone of the bladder
  • Its blood supply is from small branches of the ovarian artery
  • IMPORTANT: the ureter can get damaged during a hysterectomy (e.g. cut, tied, necrosis due to interference with blood supply)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe the rectum

A
  • The rectum begins at the level of the 3rd sacral vertebra
  • The front and sides are covered by the peritoneum of the rectovaginal pouch
  • The lower third of the rectum has no peritoneal covering and the rectum is separated from the posterior wall of the vagina by the rectovaginal fascial septum
  • Lateral to the rectum are the uterosacral ligaments alongside which run some of the lymphatics draining the cervix and vagina
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is intermenstrual bleeding?

A
  • bleeding between periods, often seen with endometrial and cervical polyps and endometriosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is post-coital bleeding?

A
  • Beeding after sex. Associated with cervical abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is postmenopausal bleeding?

A
  • Bleeding more than 1 year after cessation of periods. Exclude endometrial pathology or vaginal atrophy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is bleeding of endometrial origin?

A
  • Diagnosis of exclusion that has replaced the term ‘dysfunctional uterine bleeding (DUB)’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is the system for characterising causes of gynae pathology?

A
  • PALM- visually objective structural criteria
    • Polyps
    • Adenomyosis
    • Leiomyoma
    • Malignancy
  • COEIN- causes unrelated to structural anomalies
    • Coagulopathy
    • Ovulatory disorders
    • Endometrial
    • Iatrogenic
    • No classified
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the definition of heavy menstrual bleeding?

A
  • Blood loss of > 80 mL per period
  • As this is difficult to quantify in practice, the definition has since changed such that heavy menstrual bleeding is whatever the patient regards as being abnormally heavy
  • NOTE: methods of quantifying blood loss is impractical and inaccurate so the diagnosis relies on the patient’s perception of blood loss
    20-30% of women of reproductive age suffer from HMB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are common causes of heavy menstrual bleeding?

A
  • Polyps (endometrial)
  • Adenomyosis
  • Leiomyoma (fibroids)
  • Malignancy (endometrial and cervical carcinoma)
  • Coagulation disorders
  • Intrauterine devices (IUDs)
  • Pelvic inflammatory disease
  • Thyroid disease
  • Drug therapy (e.g. warfarin)
  • Often no pathology is identified
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are key features in history for HMB?

A
  • Heaviness of period
  • Extent to which it disrupts the woman’s life and causes anaemia
  • Did the HMB start at menarche or has it changed since?
  • Regularity of the menstrual cycle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What are irregular bleeding, PCB and IMB suggestive of?

A
  • Endometrial or cervical polyps

- Other cervical abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What are excessive bruising/bleeding from other sites, Hx of PPH, excessive postoperative bleeding, FHx of bleeding problems suggestive of?

A
  • Coagulation disorders (coagulation disorders will be present in 20% of those presenting with unexplained HMB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is unusual vaginal discharge associated with?

A
  • PID
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What are urinary symptoms, abdominal masses or abdominal fullness suggestive of?

A
  • Pressure from fibroids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What investigations should be done for HMB?

A
  • Abdominal and pelvic examinations should be performed
    • This enables palpation of pelvic masses and the visualisation of polyps/carcinomas of the cervix
    • It also allows smears to be taken
  • FBC
  • Coagulation screen if HMB since menarche or family history of coagulation defects
  • Pelvic ultrasound scan
    • If the history suggests structural/histological problem (e.g. post-coital bleeding, intermenstrual bleeding, pain/pressure symptoms or enlarged uterus/vaginal mass)
  • High vaginal or endocervical swabs
  • Endometrial biopsy
    • Only if risk factors (e.g. > 45 years, treatment failure)
    • Indications
      • PMB and endometrial thickness on TVUSS > 4 mm
      • HMB > 45 years
      • HMB associated with IMB
      • Treatment failure
      • Prior to ablative techniques
  • Thyroid function test
  • Outpatient hysteroscopy with guided biopsy if:
    • Endometrial biopsy fails
    • Endometrial biopsy sample is insufficient
    • TVUSS is inconclusive
    • Abnormality of TVUSS is amenable to treatment
  • NOTE: if the patient cannot tolerate an outpatient hysteroscopy, a hysteroscopy under GA may be needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the factors to consider when managing heavy menstrual bleeding?

A
  • Patient’s preference
  • Risks/benefits of each option
  • Contraceptive requirements (Family complete? Current contraception?)
  • Past medical history (any contraindications? Suitability for anaesthetic?)
  • Previous surgical history on uterus
  • Blood loss may be normal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What is the medical management of heavy menstrual bleeding?

A
  • Levonorgestrel Intrauterine System (LNG-IUS, Mirena)
    • Requires long-term use (at least 12 months)
    • Reduces mean blood loss
    • Should be considered in the majority of women as an alternative to surgical treatment
    • NOT suitable in women wishing to conceive
  • Tranexamic acid
    • Antifibrinolytic that reduces blood loss by 50%
    • Taken during menstruation
    • Mefenamic acid inhibits prostaglandin synthesis and reduces blood loss by 30%
    • COCP induces slightly lighter periods
  • Norethisterone
    • 15 mg daily in a cyclical pattern from day 6-26 of the menstrual cycle
  • Gonadotrophin Releasing Hormone (GnRH) agonists
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the surgical management of heavy menstrual bleeding?

A
  • Usually only considered in women for whom medical treatment has failed
  • Women contemplating surgery must be certain that their family is complete
  • Women wishing to preserve their fertility should go for medical options
  • Endometrial Ablation
    • Ablation to a sufficient depth to prevent regeneration
    • Suitable for women with a uterus < 10 weeks size and with fibroids < 3 cm
    • Methods
      • Impedance controlled endometrial ablation
      • Thermal uterine balloon therapy
      • Microwave ablation
    • 80% will have markedly reduced menstrual bleeding or become amenorrhoeic
  • Uterine Artery Embolisation
    • Useful for HMB associated with fibroids
  • Myomectomy
    • Useful for women with HMB secondary to large fibroids with pressure symptoms who wish to conceive
  • Transcervical Resection of Fibroids
    • Used for resection of large submucosal fibroids
    • May reduce HMB and is appropriate for women wishing to conceive
  • Hysterectomy
    • Surgical removal of the uterus
    • Considered in women with HMB associated with large fibroids with pressure symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the management of acute menstrual bleeding?

A

ABCDE

  • Admit
  • Pelvic examination
  • FBC, coagulopathy screen, biochemistry
  • IV access and fluid resuscitation
  • Tranexamic acid oral or IV
  • TVUSS
  • High-dose progestogens to arrest bleeding
  • Consider suppression with GnRH or ulipristal acetate
  • Longer-term plan when diagnosis has been made
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is dysmenorrhoea and what are the types?

A
  • Painful menstruation
  • Primary dysmenorrhoea = painful periods since onset of menarche (unlikely to be associated with pathology)
  • Secondary dysmenorrhoea = painful periods that have developed over time and usually have a secondary cause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What are causes of secondary dysmenorrhoea?

A
  • Endometriosis or adenomyosis
  • Pelvic inflammatory disease
  • Cervical stenosis and haematometra (rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Describe the history and examination of dysmenorrhoea?

A
  • Some patients may just need reassurance
  • Others may like the ability to alter the menstrual cycle to avoid having a period during key events (e.g. school examinations)
  • Important to distinguish between menstrual pain that precedes the period and pain that only occurs with bleeding
  • Secondary dysmenorrhoea may be associated with dyspareunia or AUB (suggesting pathology)
  • Abdominal and pelvic examination should be performed
    • Pelvic mass - endometriosis?
    • Fixed uterus - adhesions?
    • Endometriotic nodule
    • Enlarged uterus - fibroids?
    • Abnormal discharge and tenderness - PID?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Questions to gauge severity of the pain in dysmenorrhoea?

A
  • Do you need to take painkillers for this pain? Which tablets help?
  • Have you needed to take any time off work/school due to pain?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What are the investigations for dysmenorrhoea?

A
  • High vaginal and endocervical swabs
  • TVUSS is useful to detect endometriomas and adenomyosis
  • Diagnostic laparoscopy - to investigate secondary dysmenorrhoea
    • When the history suggests endometriosis
    • When swabs and ultrasound scans are normal but symptoms persist
    • When the patient wants a definitive diagnosis or wants reassurance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What is the management of dysmenorrhoea?

A
  • NSAIDs
  • COCP
    • Widely used but may not be effective
    • Progestogens may be useful to cause anovulation and amenorrhoea
  • LNG-IUS
    • Effective treatment for underlying causes (e.g. endometriosis and adenomyosis)
  • Lifestyle changes
    • Exercise and dietary (vegetarian) changes may help
  • Heat
    • Old but effective
  • GnRH analogues
    • Useful in the short-term to manage symptoms if awaiting hysterectomy
  • Surgery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What does the hypothalamus do? (O&G)

A
  • Secretes GnRH which controls pituitary hormone secretion

- GnRH is released in a pulsatile manner to stimulate pituitary secretion of LH and FSH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What does GnRH do?

A
  • GnRH stimulates basophil cells in the anterior pituitary gland which synthesise and release FSH and LH
  • This is modulated by oestrogen and progesterone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What effect does low oestrogen have on LH production?

A
  • Low oestrogen has an inhibitory effect on LH production (negative feedback)
  • The COCP maintains a constant serum oestrogen level that is within the NEGATIVE feedback range, thereby preventing an LH surge
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

How does high oestrogen affect LH production?

A
  • HIGH oestrogen will increase LH production (positive feedback)
    • This works by increasing concentrations of GnRH receptors
  • The high levels of oestrogen in the late follicular phase act via positive feedback to generate a periovulatory LH surge
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

How does low progesterone affect FSH and LH secretion?

A
  • Low progesterone has a POSITIVE feedback effect on pituitary LH and FSH secretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

How does high progesterone affect FSH and LH production?

A
  • High progesterone will INHIBIT pituitary LH and FSH production
    • This works by increasing sensitivity to GnRH in the pituitary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Describe ovulation and menstruation

A
  • Starting at menarche, the primordial follicles which had been arrested in prophase of meiotic division, will start to activate and grow in a cyclical fashion leading to ovulation and menstruation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What are the three phases the ovaries go through in a cycle?

A
  • Follicular
  • Ovulatory
  • Luteal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Describe the follicular phase

A
  • Follicular development will fail at the preantral stage and follicular atresia will occur if LH and FSH are absent
  • FSH rises in the first days of the menstrual cycle whilst oestrogen, progesterone and inhibin levels are low
  • This FSH rise will stimulate a cohort of small antral follicles to grow
  • Within the follicles there are TWO cell types:
    • Theca Cells - LH stimulates production of androgens from cholesterol
    • Granulosa Cells - convert androgens from theca cells into oestrogens via the process of aromatisation under the influence of FSH
  • As follicles grow, oestrogen secretion increases
  • This has a NEGATIVE feedback effect on FSH leading to a decrease in FSH
  • This assists in the selection of the dominant follicle (smaller follicles will undergo atresia)
  • Inhibin is secreted by the granulosa cells and downregulates FSH release and enhances androgen synthesis
  • Activin is produced by granulosa cells and the pituitary and acts to increase FSH binding on the follicles
  • NOTE: IGF-I and IGF-III also act as paracrine regulators as do Kisspeptins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Describe ovulation

A
  • By the end of the follicular phase, the dominant follicle will be about 20 mm in diameter
  • FSH induces LH receptors on the granulosa cells to compensate for lower FSH levels and prepare for the signal for ovulation
  • Production of oestrogen increases until it reaches a threshold to exert POSITIVE feedback on the hypothalamus resulting in an LH surge
  • This happens over 24-36 hours
  • LH-induced luteinisation of granulosa cells in the dominant follicle cause progesterone to be produced
  • This exerts more positive feedback for LH secretion and causes a small rise in FSH
  • The LH surge also stimulates the resumption of meiosis
  • The physical ovulation occurs after breakdown of the follicular wall under the influence of LH, FSH, proteolytic enzymes and prostaglandins
  • IMPORTANT: inhibition of prostaglandin production can affect ovulation, therefore women wanting to become pregnant should avoid taking PG synthetase inhibitors (e.g. aspirin, ibuprofen)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Describe the Luteal Phase

A
  • After release of the oocyte, the remaining granulosa and theca cells form the corpus luteum
  • It undergoes extensive vascularisation to supply granulosa cells with a rich blood supply for continued steroid production (aided by local VEGF production)
  • On going pituitary LH secretion and granulosa activity provides a supply of progesterone, which stabilises the endometrium in preparation of pregnancy
  • The progesterone also suppresses FSH and LH to prevent further follicular growth
  • The luteal phase lasts 14 days
  • In the absence of b-hCG produced by the implanting embryo, the corpus luteum will regress via luteolysis
  • The mature corpus luteum will produce less progesterone, which will eventually result in menstruation
  • A reduction in progesterone, oestrogen and inhibin feeding back to the pituitary cause increased FSH secretion
  • New preantral follicles will be stimulates and the cycle begins again
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

What happens to the endometrium during the proliferative phase?

A
  • Begins immediately after menstruation, when glandular and stromal growth begins
  • The epithelium will change from a single layer of columnar cells to pseudostratified epithelium with frequent mitoses
  • Endometrial thickness at menstruation = 0.5 mm
  • Endometrial thickness at the end of the proliferative phase = 3.5-5 mm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What happens to the endometrium during the secretory phase?

A
  • After ovulation, there is a period of secretory activity
  • After the LH surge, the oestrogen-induced proliferation is inhibited so that the endometrium does not get any thicker
  • The endometrial glands, however, become more tortuous, spiral arteries will grow and fluid is secreted into the glandular cells and uterine lumen
  • Progesterone induces the formation of a temporary layer (decidua) in the endometrial stroma
  • Apical membrane projections of epithelial cells (pinopodes) appear after day 21-22 which makes the endometrium receptive for implantation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

What happens to the endometrium during menstruation?

A
  • Shedding of dead endometrium
  • Immediately before menstruation, there are THREE layers of the endometrium:
    • Basalis - lower 25% which remains throughout the menstrual cycle
    • Stratum spongiosum - oedematous stroma and exhausted glands
    • Stratum compactum - upper 25% with prominent decidualised stromal cells
  • A fall in oestrogen and progesterone at the end of the luteal phase leads to loss of tissue fluid, vasoconstriction of spiral arterioles and distal ischaemia
  • This leads to tissue breakdown and loss of upper layers
  • NOTE: patients on HRT or COCP will have a withdrawal bleed during their pill-free week because of the lack of oestrogen and progesterone
  • Vaginal bleeding will stop after 5-10 days
  • NOTE: haemostasis is different in the endometrium because it does NOT involve clot formation and fibrosis
  • Other factors involved in menstruation: prostaglandins, endothelins, platelet activating factor, prostacyclin, nitric oxide
  • VEGF and fibroblast growth factor are powerful angiogenic agents that promote endometrial repair (requires glandular and stromal regeneration and angiogenesis)
  • Epidermal growth factor (EGF) is important in oestrogen-induced glandular and stromal regeneration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

What happens during normal puberty?

A
  • During childhood the HPO axis is suppressed and levels of GnRH, FSH and LH are very low
  • From the age of 8-9 years, the GnRH pulsations increase in amplitude and frequency
  • The increase in FSH and LH triggers follicular growth and steroidogenesis in the ovary
  • The oestrogen produced by the ovaries initiates the physical changes of puberty
  • Leptin plays a permissive role in puberty (hence why people who are very underweight will fail to go through puberty)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

What physical changes happen in puberty?

A
  • Breast development (thelarche)
  • Pubic and axillary hair growth (adrenarche)
  • Growth spurt (due to growth hormone secretion)
  • Onset of menstruation (menarche)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

What is the mean age of menarche?

A
  • Mean age of menarche = 12.8 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

What can be used to describe pubertal development?

A
  • Tanner Staging
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

What is precocious puberty?

A
  • Onset of puberty before the age of:
    • 8 in a girl
    • 9 in a boy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

How is precocious puberty classified as?

A
  • Central - gonadotrophin dependent
  • Peripheral - gonadotrophin independent
    • This is ALWAYS pathological
    • May be caused by exogenous ingestion of oestrogen or a hormone-producing tumou
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

What is delayed puberty?

A
  • When there are no signs of secondary sexual characteristics by age of 14 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

What are the central defect causes of delayed puberty?

A
  • Anorexia nervosa
  • Excessive exercise
  • Chronic illness
  • Kallmann’s syndrome
  • May be associated with delayed puberty and primary amenorrhoea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

What are the causes of delayed puberty related to gonadal failure?

A
  • Caused by gonadal failure (it does NOT respond to gonadotrophins)
  • Associated with Turner syndrome and XX gonadal dysgenesis
  • Premature ovarian failure can occur at any age (may be idiopathic, autoimmune, metabolic, or following chemo/radiotherapy in childhood)
  • Associated with delayed puberty and primary amenorrhoea
  • It can also occur later in life and cause secondary amenorrhoea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

What are the features of Turner Syndrome?

A
  • 45X
  • Most common chromosomal abnormality in females
  • It can also cause a mosaic karyotype
  • Main clinical features
    • Short stature
    • Webbing of the neck
    • Wide carrying angle
  • Associated medical condition
    • Coarctation of the aorta
    • Inflammatory bowel disease
    • Sensorineural and conduction deafness
    • Renal anomalies
    • Endocrine dysfunction (e.g. thyroid disease)
  • The ovary does NOT complete its normal development and only stroma is present at birth
  • The gonads are called streak gonads and do NOT function to produce oestrogen or oocytes
  • Diagnosis is made at birth (except in 10% of cases)
  • As the gonads do NOT produce oestrogen, the physical changes of puberty do not happen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

What is the management of Turner syndrome?

A
  • During childhood, the focus is on growth
  • In adolescence, it focuses on the induction of puberty
  • Pregnancy is only possible with ovum donation
  • In girl with mosaicism, they may undergo normal puberty and menstruation may occur
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

What is 46 XY Gonadal Dysgenesis?

A
  • The gonads do not develop into testis
  • May be due to SRY gene mutation
  • In complete gonadal dysgenesis (Swyer syndrome), the gonad remains as a streak and does not produce any hormones
  • The absence of anti-Mullerian hormone, the Mullerian structures (uterus, vagina and Fallopian tube) will develop normally
  • The absence of testosterone means the foetus does NOT virilise
  • The baby is phenotypically FEMALE but has an XY chromosome
  • The gonads do NOT function and the patient will present with delayed puberty
  • The dysgenetic gonad has a high malignancy risk and should be removed when the diagnosis is made
  • Puberty must be induced with oestrogen
  • Pregnancy may be possible with a oocyte donor
  • In mixed gonadal dysgenesis, both functioning ovarian and testicular tissue can be present (this is known as ovotesticular DSD)
  • The anatomical findings depend on the function of the gonads
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What is 46 XY DSD?

A
  • Most common cause is complete androgen insensitivity
  • In this condition, virilisation of the external genitalia does NOT occur due to partial or complete inability of the androgen receptor to respond to androgen stimulation
  • In these patients, testes form normally due to action of the SRY gene
  • The testes will secrete anti-Mullerian hormone leading to regression of the Mullerian ducts (so they do NOT have a uterus)
  • Testosterone is also produced BUT the androgen receptors does NOT respond so the external genitalia does NOT virilise and instead undergoes female development
  • The baby is born with:
    • Normal female external genitalia
    • Absent uterus
    • Test found somewhere in the line of descent
  • Presentation is usually at puberty with primary amenorrhoea
  • NOTE: the testes could cause a hernia
  • Initial diagnosis should be accompanied by:
    • Psychological support
    • Full disclosure of the XY karyotype
    • Information about infertility
  • Gonadectomy is recommended because of the small long-term risk of testicular malignancy
  • Long-term HRT will be required
  • The vagina may need to be lengthened to be suitable for penetrative intercourse (vaginal dilatation)
  • In partial androgen insensitivity, the patient may be partially virilised and the baby may be diagnosed at birth with ambiguous genitalia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

What is 5-alpha reductase deficiency?

A
  • The foetus is XY and has normal functioning testes that both produce testosterone and AMH
  • BUT, the foetus cannot convert testosterone to DHT so CANNOT virilise normally
  • Presentation is usually with ambiguous genitalia
  • It may also present with increasing virilisation of a female child at puberty
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

What is 46 XX DSD?

A
  • Most common cause is congenital adrenal hyperplasia (CAH)
  • Causes virilisation of the female foetus
  • Enzyme deficiency in the corticosteroid synthesis pathway (mainly 21-hydroxylase - converts progesterone to deoxycorticosterone and 17-hydroxyprogesterone to deoxycortisol) leads to shunting of precursors into the androgen synthesis pathway
  • Reduced negative feedback due to low output of cortisol leads to adrenal hyperplasia
  • Physical Changes due to Virilisation
    • Enlarged clitoris
    • Fused labia (scrotal in appearance)
    • Upper vagina joins the urethra and opens as one common channel into the perineum
  • 2/3 with 21-hydroxylase deficiency will have a salt-losing variety due to inadequate aldosterone production (can cause a salt-losing crisis soon after birth)
  • Affected individuals require lifelong steroid replacement
  • Surgical treatment of the genitalia may be considered
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What is the definition of amenorrhoea?

A
  • Absence of menstruation for more than 6 months in the absence of pregnancy in a woman of fertile age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

What is primary amenorrhoea?

A
  • When a girl fails to menstruate by 16 years of age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

What is secondary amenorrhoea?

A
  • Absence of menstruation for > 6 months in a normal female of reproductive age that is not due to pregnancy, lactation or menopause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

What is oligomenorrhoea?

A
  • Irregular periods at intervals of more than 35 days , with only 4-9 periods per year
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

What are the causes of hypothalamic disorders?

A
  • Excessive exercise, weight loss and stress
  • Hypothalamic lesions (craniopharyngioma, glioma)
  • Head injuries
  • Kallmann’s syndrome (genetic condition causing lack of GnRH)
  • Systemic disorders (sarcoidosis, TB)
  • Drugs (progestogens, HRT, dopamine antagonists)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

What are the causes of pituitary disorders?

A
  • Adenomas (prolactinoma is most common)
  • Pituitary necrosis (e.g. Sheehan’s syndrome)
  • Iatrogenic (surgery, radiotherapy)
  • Congenital failure of pituitary development
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

What are causes of hypogonadotrophic hypogonadism?

A
  • Hypothalamic and Pituitary disorders

- Polycystic ovarian syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

What are examples of some ovarian disorders that cause amenorrhoea/oligomenorrhoea?

A
  • Polycystic ovarian syndrome (PCOS)
    • This causes hypergonadotrophic hypogonadism
  • Premature ovarian failure: cessation of periods < 40 years of age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

What are some endometrial disorders that cause amenorrheoa/oligomenorrhoea?

A
  • Primary amenorrhoea may result from Mullerian defects in the genital tract (e.g. absent uterus) causing haematocolpos (vagina filled with blood)
  • Secondary amenorrhoea may be due to scarring of the endometrium (Asherman syndrome)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

What investigations would you do for amenorrhoea/oligomenorrhoea?

A
  • A pregnancy test should be carried out if the patient is sexually active
  • Blood can be taken to measure hormone levels
    • Raised LH + raised testosterone –> PCOS
    • Raised FSH –> POF
    • Raised prolactin –> prolactinoma
    • Thyroid function if clinically indicated
  • Ultrasound would be useful to visualise polycystic ovaries
  • MRI can be used to visualise the pituitary gland
  • Other investigations include:
    • Hysteroscopy - Asherman syndrome, cervical stenosis
    • Karyotyping - Turner’s and other chromosomal abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

What are the features of polycystic ovarian syndrome?

A
  • Cardinal features:
    • Hyperandrogenism
    • Polycystic ovarian morphology
  • About 25% of all women have polycystic ovaries on ultrasound but it does not always cause the full syndrome
  • Associated with an increased risk of:
    • T2DM
    • Cardiovascular events
  • It tends to have a familial trend
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

What are the clinical features of PCOS?

A
  • Oligomenorrhoea/amenorrhoea due to chronic anovulation in 75%
  • Hirsutism
  • Subfertility in up to 75%
  • Obesity in at least 40%
  • Acanthosis nigricans
  • May be ASYMPTOMATIC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

How do you diagnose PCOS?

A
  • Rotterdam Consensus Criteria - must have TWO of THREE features:
    • Amenorrhoea/oligomenorrhoea
    • Clinical or biochemical hyperandrogenism
    • Polycystic ovaries on ultrasound
      • 12 or more subcapsular follicular cysts < 10 mm in diameter and increased ovarian stroma
  • NOTE: they will also have high LH
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

What is the management of PCOS?

A
  • COCP to regulate menstruation
    • This increases sex hormone-binding globulin which helps relieve androgenic symptoms
  • Cyclical oral progesterone
    • Regulate the withdrawal bleed
  • Clomiphene
    • Induce ovulation if subfertility is an issue
    • It is a selective oestrogen receptor modulator (SERM)
  • Lifestyle advice
    • Dietary modification and exercise if at increased risk of developing T2DM and cardiovascular disease
  • Weight reduction
  • Ovarian drilling
    • Procedure that destroys the ovarian stroma and may prompt ovulatory cycles
  • Treatment of androgenic/hirsutism symptoms
    • Topical eflornithinecream
    • Cyproterone acetate (antiandrogen)
    • Metformin
    • GnRH analogues (reserved for women who are intolerant of other therapies)
    • Surgical treatment (laser or electrolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

What is premenstrual syndrome?

A
  • Occurrence of cyclical somatic, psychological and emotional symptoms occurring in the luteal phase
  • They resolve by the time menstruation ceases
  • Clinical Features
    • Bloating
    • Cyclical weight gain
    • Mastalgia
    • Abdominal cramps
    • Fatigue
    • Headache
    • Depression
    • Irritability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

What is conservative management of PMS?

A
  • Stress reduction
  • Alcohol and caffeine limitation
  • Exercise
  • Alternatives:
    • Vitamins
    • St John’s wort
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

What is the medical management of PMS?

A
  • COCP
    • Bicycling or tricycling pill packets (taking 2 or 3 without a scheduled break) is effective
    • NOTE: it is recommended that low-dose progesterone is also given as this
  • Transdermal oestrogen
    • Reduces symptoms by overcoming the fluctuations in a normal cycle
  • GnRH analogues
    • Turn off ovarian activity
    • HRT should also be administered to prevent osteoporosis
  • SSRIs (severe PMS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Apart from conservative and medical management, what else can be done for PMS?

A
  • CBT (for depression)
  • LAST RESORT: Hysterectomy with bilateral salpingo-oophorectomy
    • Only if all other measures fail
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

What does the corpus luteum do after ovulation?

A
  • After ovulation, the corpus luteum produces large amounts of progesterone
  • The progesterone prepares the endometrium to support a pregnancy
  • Successful implantation is when the oocyte is fertilised in the Fallopian tube and implants in the endometrium around 7 days after ovulation
  • The implanted blastocyst secretes hCG which acts on the corpus luteum to rescue it from luteolysis to maintain progesterone secretion, prevent menstruation and support the early conceptus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

How long does the corpus luteum support pregnancy?

A
  • 8 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

What is the main supply of progesterone after the corpus luteum?

A
  • The early placental tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

What is biochemical pregnancy?

A
  • A positive pregnancy test could occur prior to the time of the expected period, followed by a negative pregnancy test after the period
  • A positive pregnancy test could occur prior to the time of the expected period, followed by a negative pregnancy test after the period
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

When can a TVUSS detect an early intrauterine gestational sac?

A
  • At around 5 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

When is the foetal heartbeat visible (TVUSS)?

A
  • 6 week gestation
98
Q

How does serum hCG change during early pregnancy?

A
  • Doubles every 48 hours
99
Q

What is confirmed as intrauterine on TVUSS for a normal pregnancy?

A
  • Serum hCG > 1500 U/L
100
Q

What is miscarriage and its main clinical feature?

A
  • Pregnancy that ends spontaneously before 24 weeks of pregnancy
101
Q

What is the incidence of miscarriage?

A
  • Occurs in 10-20% of clinical pregnancies

- Risk increases with maternal age

102
Q

What are the aetiological factors for miscarriage?

A
  • Chromosomal abnormalities
  • Medical/endocrine disorders
  • Uterine abnormalities
  • Infections
  • Drugs/chemicals
103
Q

What investigations should be done for miscarriage?

A
  • ABCDE
  • Abdomino-pelvic examination
  • Address psychological symptoms
  • TVUSS
    • Can diagnose a miscarriage if there is no pregnancy within the uterine cavity
  • Haemoglobin and group and save (or cross-match if severely compromised)
    • Measure to assess degree of vaginal loss and rhesus status
104
Q

What is the management of threatened miscarriage according to the NICE guidelines?

A
  • If the woman has vaginal bleeding and a confirmed intrauterine pregnancy with a foetal heart beat:
    • Return for further assessment if the bleeding gets worse or persists beyond 14 days
    • Continue routine antenatal care if the bleeding stops
105
Q

What is expectant management of miscarriage according to the NICE guidelines?

A
  • Use expectant management for 7-14 days as FIRST LINE in women with confirmed miscarriage
  • Explore other options if:
    • Increased risk of haemorrhage (e.g. late first trimester)
    • Previous adverse/traumatic event associated with pregnancy
    • Increased risk from effects of haemorrhage (e.g. unable to have blood transfusion)
    • Evidence of infection
  • Offer medical management if expectant management is not acceptable
  • If bleeding and pain resolves within 7-14 days of starting expectant management, advise taking a pregnancy test after 3 weeks and returning to see the doctor if it is positive
  • Offer repeat scan if after the period of expectant management the bleeding and pain:
  • Has not started (suggests miscarriage has not begun)
  • Persisting and/or increasing (suggesting incomplete miscarriage)
106
Q

What is the medical management for miscarriage?

A
  • Do NOT offer mifepristone for miscarriage
  • Offer vaginal misoprostol (oral preparation can also be used depending on patient preference)
  • If the bleeding has NOT started within 24 hours of treatment, contact a healthcare professional
  • Offer pain relief and anti-emetics to all patients undergoing medical management of miscarriage
  • Inform patient about what to expect: vaginal bleeding, pain, diarrhoea and vomiting
  • Advise taking pregnancy test 3 weeks after medical management
  • NOTE: medical management has a 10% failure rate
107
Q

What is the surgical management for miscarriage?

A
  • Manual vacuum aspiration under local anaesthetic
  • Surgical management in theatre under general anaesthetic
  • Vaginal or sublingual misoprostol if often used to ripen the cervix to facilitate cervical dilatation for suction insertion
  • Offer anti-D prophylaxis to all Rhesus-negative women undergoing surgical management of miscarriage
108
Q

What is recurrent miscarriage?

A
  • Loss of three or more consecutive pregnancies

- Affects 1% of couples

109
Q

What are the risk factors for recurrent miscarriage?

A
  • Advancing maternal and paternal age
  • Obesity
  • Balanced chromosomal translocations
  • Uterine structural anomalies
  • Antiphospholipid syndrome
110
Q

What are the causes of recurrent miscarriage?

A
  • Antiphospholipid syndrome
  • Cervical abnormalities
  • Foetal chromosomal abnormalities
  • Uterine malformations
  • Thrombophilia
111
Q

What investigations should be done for recurrent miscarriage? (Green Top Guidelines)

A
  • Screen for antiphospholipid syndrome
    • Lupus anticoagulant
    • Anti-cardiolipin antibodies
    • DIAGNOSTIC: 2 positive results at least 12 weeks apart
  • Cytogenetic analysis
    • Of products of conception in the last miscarriage
    • Of both partners peripheral blood
  • Transvaginal ultrasound to assess for uterine anomalies
  • Screen for inherited thrombophilia (e.g. factor V leiden)
112
Q

What is the management of recurrent miscarriage (Green Top Guidelines)?

A
  • Anti-phospholipid syndrome
    • Low-dose aspirin + LMWH in future pregnancy reduces risk of miscarriage by 54%
  • NOTE: steroids and IVIG have NO proven benefit
  • If abnormal parental genetics are found, refer to clinical geneticist
  • Cervical issues may be treated with cerclage
113
Q

What is an ectopic pregnancy?

A
  • Implantation of a pregnancy outside the normal uterine cavity
  • Over 98% of ectopic pregnancies will implant in the Fallopian tube
  • Rare sites: interstitium of the tube, ovary, cervix, abdominal cavity or C-section scars
114
Q

What is a heterotopic pregnancy?

A
  • Simultaneous development of two pregnancies, one within and one outside the uterine cavity
    • Incidence is higher in patients receiving IVF
115
Q

What is the incidence of ectopic pregnancy?

A
  • 1 in 80 pregnancies

- Responsible for 9-13% of maternal deaths

116
Q

What is the aetiology of ectopic pregnancy?

A
  • Fallopian tube damage due to pelvic infection, previous ectopic pregnancy and previous tubal surgery
  • Functional alterations in the Fallopian tube due to smoking and increased maternal age
  • Previous abdominal surgery
  • Subfertility
  • IVF
  • Use of intrauterine contraceptive devices
  • Endometriosis
  • Conception on oral contraceptive/morning after pill
117
Q

What is the clinical presentation of ectopic pregnancy?

A
  • Abdominal pain and/or vaginal bleeding in early pregnancy
  • Rarely, patients will present very acutely with rupture of the ectopic pregnancy and massive intraperitoneal bleeding
    • The free blood in the peritoneal cavity can cause diaphragmatic irritation and shoulder tip pain
  • Signs of acute abdomen and hypovolaemic shock with a positive pregnancy test
118
Q

What are the investigations for ectopic pregnancy?

A
  • ABCDE
  • Abdominopelvic examination
  • TVUSS
    • Identification of intrauterine pregnancy excludes ectopic pregnancy (except with heterotopic pregnancy)
    • Ectopic pregnancy will appear as an empty uterus with an adnexal mass
    • Presence of moderate to significant free fluid on TVUSS is suggestive of a ruptured ectopic pregnancy
  • Serum hCG
    • Should double every 48 hours in a normal pregnancy
    • In ectopic pregnancy, the rise in hCG is often suboptimal
    • Serial measurements 48 hours apart may show this
  • Haemoglobin and Group and Save (or crossmatch if severely compromised)
    • Measure to assess degree of intra-abdominal bleeding and Rhesus status
119
Q

What is pregnancy of unknown location?

A
  • In 40% of women with ectopic pregnancy, the diagnosis is NOT made on first attendance and are labelled as having pregnancy of unknown location (PUL)
  • TVUSS shows an empty uterus with no evidence of an adnexal mass in a patient with a positive pregnancy test
  • Investigate with consecutive measurement of serum hCG
  • Endometrial biopsy may be helpful if hCG levels are static
120
Q

What is the expectant management of ectopic pregnancy? (NICE guidelines)

A
  • Based on the assumption that a significant proportion of ectopic pregnancies will resolve without treatment
  • Suitable for patients who are haemodynamically stable and asymptomatic
  • The patient should have serial hCG measurements until the levels are undetectable
121
Q

What is the medical management of ectopic pregnancy? (NICE guidelines)

A
  • Provide advice on how to contact a healthcare professional if needed and when to get help in an emergency
  • Offer IM METHOTREXATE as 1st line if able to attend follow-up and provided that all of the following criteria are fulfilled:
    • No significant pain
    • Unruptured ectopic pregnancy with adnexal mass < 35 mm with no visible heartbeat
    • Serum b-hCG < 1500 iU/L
    • No intrauterine pregnancy (confirmed by USS)
    • FOLLOW-UP
      • Take 2 serum hCG measurements at days 4 and 7
      • Take 1 serum hCG per week until a negative result is obtained
      • Avoid sexual intercourse during treatment
      • Avoid conceiving for 3 months after methotrexate
      • Avoid alcohol and prolonged exposure to sunlight
  • Offer a CHOICE of either methotrexate or surgery if b-hCG 1500-5000 iU/L and:
    • No significant pain
    • Unruptured ectopic with adnexal mass < 35 mm with no visible heartbeat
    • No intrauterine pregnancy identified on USS
  • IMPORTANT: methotrexate carries a greater risk of urgent re-admission
122
Q

What is the surgical management of ectopic pregnancy? (NICE guidelines)

A
  • Offer SURGERY as 1st line if unable to return for follow-up or any of the following:
    • Significant pain
    • Adnexal mass > 35 mm
    • Ectopic pregnancy with a foetal heartbeat visible on ultrasound scan
    • Serum b-HCG > 5000 iU/L
  • SURGERY
    • Laparoscopic where possible
    • Offer salpingectomy unless there are other risk factors for infertility
    • Consider salpingotomy if there are risk factors for infertility or contralateral tubal damage
    • WARNING: 1 in 5 women who have salpingotomy need further treatment (methotrexate and/or salpingectomy)
    • FOLLOW-UP for Salpingotomy: 1 serum hCG at 1 weeks, then 1 serum hCG per week until negative result is obtained
    • FOLLOW-UP for Salpingectomy: urine pregnancy test at 3 weeks
123
Q

How is anti-D prophylaxis relevant to ectopic pregnancy?

A
  • Offer anti-D prophylaxis (250 iU) to all RhD-negative women who have a SURGICAL management of ectopic pregnancy or miscarriage
  • Do NOT do Kleihauer test
  • Do NOT offer anti-D prophylaxis if:
    • Solely medical management
    • Threatened miscarriage
    • Complete miscarriage
    • Pregnancy of unknown origin
124
Q

What is the mechanism of actions for contraceptives?

A
  • Prevent ovulation
    • Combined hormonal methods (pill, patch and vaginal ring)
    • Progesterone-only injectables
    • Progesterone-only implant (Nexplanon)
    • Oral emergency contraception
    • Lactational amenorrhoea
  • Prevent sperm reaching the oocyte
    • Female sterilisation
    • Male sterilisation (vasectomy)
  • Prevent an embryo implanting in the uterus
    • Cu-IUD
    • LNG-IUS
  • Poison sperm that enter the vagina
    • Spermicides
  • Block the passage of sperm beyond the vagina
    • Diaphragm
    • Cap
    • Progestogens
  • Prevent sperm entering the vagina
    • Male and female condoms
    • Avoid sex during the fertile time of the cycle
    • Fertility awareness-based methods (FAB)
125
Q

What is LARC?

A
  • LARC is defined in the UK as a method that requires administration less than once per month (e.g. injectable, implant, IUD)
126
Q

What is the WHO medical eligibility criteria?

A
  • The WHO medical eligibility criteria (MEC) is a guidance document with recommendations for whether or not a woman with medical conditions is eligible to use a particular contraceptive method
  • Category 4 = ABSOLUTE contraindication
127
Q

How does contraception interact with other medicines?

A
  • Several medicine (e.g. anticonvulsants, antifungals, antibiotics, antiretrovirals) induce liver enzymes and reduce the efficacy of hormonal contraception such as pills, patch and ring
  • If a woman using enzyme-inducing medication wants to use hormonal methods of contraception, consistent use of condoms is also advised
  • Effectiveness of the COCP is not affected by administration of most broad-spectrum antibiotics
128
Q

What contraception methods are not affected by enzyme induction?

A
  • Cu-IUD
  • LNG-IUS
  • Progesterone-only injectable
129
Q

What are side effects of contraception?

A
  • Unexpected bleeding
  • Weight gain (IMPORTANT)
  • Headaches
  • Mood swings
  • Loss of libido
  • There is no evidence that hormonal methods (except the progestogen-only injectable) causes weight gain
  • There is no evidence that the intrauterine methods cause weight gain
  • Unexpected bleeding is common and may settle with time
    • If it does NOT settle, changing the contraceptive or using a different dose may help
    • If bleeding continues for > 3 months, investigations to exclude other causes (e.g. polyps, chlamydia infection) should be considered
  • If women using COCP experience headaches in the pill-free week, they may benefit from continuing packets of pills to avoid the hormone-free interval
  • If headaches occur during the use of the hormonal method that are severe, frequent or migraine, changing the method of contraception is advisable
130
Q

What are the determinants of contraceptive method acceptability?

A
  • Personal characteristics (e.g. age)
  • Fertility intentions
  • Perceptions of effectiveness
  • Perceptions of safety
  • Fear of side-effects
  • Familiarity
  • Experience of others
  • Ease of use and of access
  • Need to see a health professional
  • Intrusiveness
  • Non-contraceptive benefits
131
Q

What do women to know before starting a method of contraception?

A
  • How to use the method and what to do when misused (e.g. missed pill)
  • Typical failure rates
  • Common side-effects
  • Health benefits
  • Fertility returning on stopping
  • When she requires review
132
Q

What hormones does the combined hormonal contraception contain?

A
  • Oestrogen

- Progestogen

133
Q

What formulation can combined hormonal contraception come in?

A
  • Oral pill
  • Transdermal patch
  • Vaginal ring
  • They are similar in terms of effectiveness, safety and side-effects
  • They work by inhibition of ovulation via negative feedback of oestrogen and progestogen on the pituitary with suppression of FSH and LH
134
Q

Describe the combined contraceptive pill?

A
  • Most commonly used COCPs contain ethinyl oestradiol (15-35 mcg)
  • Some newer pills contain oestradiol valerate or oestradiol hemihydrate
  • Most preparations contain 21 pills followed by a 7-day pill-free interval (or 7 placebo tablets)
  • Some preparations will contain 24 pills with a shorter pill-free interval
  • Preparations are usually monophasic (same dose of hormones throughout)
  • The 21 days on 7 days off regimen usually results in a withdrawal bleed during the pill-free interval
  • IMPORTANT: there is no reason why women cannot take the pill continuously
  • Women with dysmenorrhoea or headaches during the pill-free interval are advised to avoid recurrence of symptoms by tricycling (taking 3 packets without a break)
135
Q

How are the progestogens in the pill categorised?

A
  • 2nd Generation: levonorgestrel, norethisterone
  • 3rd Generation: gestodene desogestrel
  • 4th Generation: drospirenone, dienogest
  • IMPORTANT: 2nd generation progestogens are recommended because 3rd and 4th generation progestogens are associated with an increased risk of venous thrombosis
136
Q

Describe the combined hormonal contraceptive patch

A
  • Combined hormonal transdermal patch releases 33.9 mcg ethinyl oestradiol per day and norelgestromin 203 mcg/day
  • It is applied to the skin of the lower abdomen, buttock or arm for 7 days
  • Usually involves application of patches for a total of 21 days followed by a 7-day hormone free interval
  • Continued use (tricycling) is also possible
  • Problems include patch adherence or skin sensitivity
137
Q

Described the combined hormonal ring

A
  • Flexible ring of 54 mm diameter that releases 15 mcg ethinyloestradiol and 120 mcg etonorgestrel daily
  • This is lowest dose combined hormonal method
  • The ring is inserted and worn in the vagina for 21 days followed by a 7-day hormone free period during which withdrawal bleeding occurs
  • Women should not feel discomfort from the ring
138
Q

Describe missed pills, patches, rings

A
  • Missed pills are common
  • 2 or more missed pills places the woman at risk of ovulation
  • Additional contraceptive cover (condoms or abstinence) is required for most monophasic ethinyloestradiol-containing pills during the next 7 days of pill taking
  • Additional precautions should also be taken if:
    • Patch is not applied for 48 hours
    • Ring is not applied for more than 3 hours
  • If sexual intercourse has occurred during this time, there is a risk of pregnancy and emergency contraception is recommended
139
Q

What are the cancer risks in COCP users?

A
  • 12% reduced risk of any cancer
  • Reduced risk of colorectal, endometrial and ovarian cancer
  • Increased risk of breast cancer during use
  • Increased risk of cervical cancer
  • Protection from endometrial and ovarian cancer seems to persist for more than 15 years after stopping the pill
  • The risk of breast cancer is increased during use, but will decrease to the same as women who have never used the pill after 10 years
140
Q

Describe the risk of VTE and arterial disease with the COCP

A
  • CHC increases the tendency to thrombosis
  • The absolute risk of thrombosis is VERY SMALL and much less than that associated with pregnancy
  • Risk is greatest within the first year of use
  • Women should be asked about personal or family history of VTE (contraindications)
  • Women > 35 years who smoke are NOT eligible for CHC because of an increased risk of arterial disease
  • It is also contraindicated in women who have migraine with aura as this condition is associated with cerebral vasospasm and women may be at increased risk of stroke if they use a CHC
141
Q

What are the formulations of the progestogen-only contraceptive methods?

A
  • Oral
  • Injectable
  • Implant
  • Intrauterine system
  • The injectable, implant and desogestrel-containing progestogen-only pill inhibit ovulation
  • All progestogen-only contraceptives thicken cervical mucus thereby reducing sperm penetrability and transport
  • The LNG-IUS has little effect on ovarian activity but causes marked endometrial atrophy meaning that implantation is not possible
142
Q

Describe the Progestogen-only pill? (POP)

A
  • Needs to be taken continuously
  • Medium-dose pills (e.g. desogestrel) inhibit ovulation in 99% of cycles
  • Lower-dose pills inhibit ovulation less frequently and rely on thickening of cervical mucus for its contraceptive effect
  • If MISSED, the woman should continue taking POP and use extra precautions (e.g. condoms) for the next 48 hours
  • If unprotected sex occurs during this time, emergency contraception is recommended
143
Q

What are the side effects of POP?

A
  • Irregular bleeding
  • Persistent ovarian follicles (simple cysts)
  • Acne
144
Q

Describe the progestogen only implant

A
  • Currently available method: single rod (Nexplanon) containing progestogen etonorgestrel
  • Nexplanon contains 68 mg of 3-keto-desogestral
  • Provides contraception for 3 years
  • Initial release arte of 60-70 mcg/day
  • Other types of implant: Uniplant, Jadelle
  • Nexplanon is inserted subdermally 8 cm above the medial epicondyle usually in the non-dominant arm under local anaesthesia
  • The implant is NOT visible but should be easily palpable
  • It shows up on X-rays
  • Once inserted, there is NO need for follow-up until the device is due for removal
  • Fertility is restored immediately after removal
145
Q

What is the most commonly used progestogen-only injectable?

A
  • A depot injection of medroxyprogesterone acetate
146
Q

What are the administrations of progestogen-only injectables?

A
  • IM Depoprovera (150 mg)

- SC Sayana press (104 mg)

147
Q

Describe the use of progestogen-only injectables

A
  • Injection interval = 12-14 weeks
  • Similar bleeding pattern for both - 50% amenorrhoea rates at 1 year
  • SC injections are more practical
  • May delay return of fertility after discontinuation - may take up to 1 year after the last injection for ovulation to return
  • No long-term change in fertility but will be inappropriate for women requiring short-term contraception
  • May cause weight gain in some patients and loss of bone mineral density
    • NOTE: this has not been associated with osteoporotic fractures and is reversible once it is stopped
148
Q

Describe the progestogen-releasing intrauterine system

A
  • TWO LNG-IUS available in Europe and USA:
    • 52 mg LNG-IUS (Mirena)
      • Licensed for 5 years for contraceptive use
  • 13.5 mg LNG-IUS (Jaydess)
    • Licensed for 3 years for contraceptive use
    • Slightly smaller which may make insertion easier in young/nulliparous women
    • Has a silver band at the proximal end helping distinguish it on ultrasound
  • LNG-IUS works by preventing endometrial proliferation and implantation
  • The progestogens also thicken cervical mucus

It does NOT prevent ovulation

  • Many women experience unpredictable bleeding in the first few months
  • This usually improves with time
  • NOTE: 13.5 mg LNG-IUS is NOT licensed as a treatment for HMB but may reduce blood loss to some extent
149
Q

What are side effects of Progestogen-releasing Intrauterine System?

A
  • Acne
  • Breast tenderness
  • Mood disturbance
  • Headaches
150
Q

What are the non-contraceptive benefits of LNG-IUS?

A
  • Reducing heavy menstrual bleeding
  • Treating dysmenorrhoea
  • Reducing pain associated with endometriosis and adenomyosis
  • Protecting the endometrium against hyperplasia
151
Q

What are the types of intrauterine contraception?

A
  • Cu-IUD
    • Used for 3-10 years
    • If a woman has a Cu-IUD inserted at > 40 years, it can be left until menopause
    • IMPORTANT: can be used as EMERGENCY CONTRACEPTION
  • LNG-IUS
    • If a woman has an LNG-IUS inserted at > 45 years, it can be left until menopause
  • Both have threads that protrude out of the cervical canal into the upper vagina for easy removal
  • These methods do NOT delay the return of fertility or increase the risk of infertility
152
Q

What are the modes of action of intrauterine contraception?

A
  • Stimulate an inflammatory reaction in the uterus
  • Concentration of macrophages, leucocytes, prostaglandins and enzymes increase significantly
  • These are toxic to both the sperm and the egg
  • Inhibits implantation
153
Q

What are the bleeding patterns with IUD?

A
  • LNG-IUS = tend to experience lighter, less painful menses
  • Cu-IUD = may experience more painful or heavier menses
  • NSAIDs may help lessen the pain and blood loss
  • Tranexamic acid during menses may also reduce blood loss with the Cu-IUD
  • If the heavy bleeding becomes a problem, the woman can switch to an LNG-IUS
154
Q

What are the risks of intrauterine contraception?

A
  • Risk of ectopic pregnancy is much lower compared to women using NO contraception
  • However, if a pregnancy does occur whilst the IUD is in situ, the relative risk of the pregnancy being ectopic is higher
  • If a woman becomes pregnant with an IUD, an ultrasound scan should be performed to exclude an ectopic pregnancy
  • IUDs should be removed before 12 weeks gestation
155
Q

What are the risks of leaving the IUD in situ?

A
  • Miscarriage
  • Preterm delivery
  • Septic abortion
  • Chorioamnionitis
156
Q

What are the perforation and expulsion risks of inserting an IUD?

A
  • Perforation
    • Especially if breastfeeding or < 6 months postpartum
    • Usually presents with ‘missing threads’ and severe pain following insertion
    • Ultrasound will show no IUD in the uterus
    • Abdominal X-ray shows an IUD
    • Laparoscopic removal is possible in most cases
  • Expulsion
    • 1 in 20 will be expelled in the first 3 months after insertion
    • After this, the risk of expulsion diminishes
    • IUD users should be advised to regularly check the presence of threads in the upper vagina
157
Q

What are the infection and “missing threads” risk of IUD insertion?

A
  • Infection
    • 1 in 100 risk of pelvic infection in the first 3 weeks after insertion
    • Thereafter, the risk is the same as normal women
    • In most cases, IUD can be left in situ and antibiotics commenced
    • Actinomyces-like organisms (ALOs) are commonly identified on cervical smears of women with and without IUDs
    • If ALOs are present in a women with an IUD who has symptoms of infection, the device should be removed and penicillin-based antibiotics given
    • Women should also be tested for STIs before insertion of the IUD
    • Prophylactic antibiotics should be given to women at high risk of infection if insertion needs to be done before test results (e.g. emergency Cu-IUD)
  • Missing threads
    • May indicate pregnancy, expulsion or perforation
    • Pregnancy test should be performed and emergency contraception/alternative contraception provided until the IUD an be confirmed to be in situ
    • This can be done by visualisation of threads on speculum examination or an ultrasound
158
Q

What are some barrier contraception?

A
  • Condoms
    • Protect against STIs including HIV
    • Only reversible male method
    • Failure rates of 24%
    • Female condoms are inserted into the vagina
  • Diaphragm and Cap
    • Latex or non-latex devices that are inserted into the vagina to prevent passage of sperm into the cervix
    • They can be inserted before sex
    • Caps fit over the cervix
    • Diaphragms form a hammock between the post-fornix and the symphysis pubis
    • Often used in conjunction with a spermicide
    • Women need to be taught how to correctly insert and remove the device
    • Failure rate = 18%
    • May be associated with increased vaginal discharge and UTIs
  • Spermicides
    • Spermicides alone are NOT recommended for prevention of pregnancy
    • Nonoxynol 9 is a spermicidal product sold for use with diaphragm and caps
    • May increase HIV transmission
    • NOT recommended for women who are at high risk of HIV
159
Q

What is female sterilisation and its three approaches?

A
  • Permanent method of contraception preventing the sperm reaching the oocyte in the Fallopian tube
  • Three approaches
    • Laparoscopy
    • Hysteroscopy
    • Laparotomy (e.g. at C-section)
160
Q

What is laparoscopic sterilisation?

A
  • Most commonly occludes the Fallopian tube using Filshie clips
  • Effective contraception should be used until the next menses after the procedure
  • Women with a high surgical risk may be better suited to a hysteroscopic approach
  • Valid consent is very important as this leads to permanent loss of fertility
161
Q

What are some advise for women considering sterilisation?

A
  • Method is irreversible
  • Vasectomy is safer, quicker and associated with less morbidity
  • High proportion of women regret sterilisation
  • Does not protect against STIs
  • Effective contraception is required until the menstrual period following laparoscopic procedure or 3 months following hysteroscopic procedure
  • Pregnancy following female sterilisation is rare but has an increased risk of ectopic pregnancy
  • Reversal is highly skilled and difficult
162
Q

What is hysteroscopic sterilisation?

A
  • Can be performed as an outpatient without general anaesthetic
  • Expanding springs (microinserts) are inserted into the tubal ostia via a hysteroscope
  • These induce fibrosis in the cornual section of each Fallopian tube over 3 months
  • Contraception is required during these 3 months and can be discontinued once correct placement of the inserts is confirmed by X-ray or ultrasound
163
Q

What is a vasectomy?

A
  • Interrupting the vas deferens to provide permanent occlusion
  • Small risk of scrotal haematoma and infection
  • Post-vasectomy semen analysis should be conducted at 12 weeks to confirm the absence of spermatozoa in the ejaculate
164
Q

What are fertility awareness-based methods?

A
  • Aka natural family planning
  • Relies on avoidance of intercourse during the fertile period
  • Failure rates are high
165
Q

What is the calendar or rhythm method?

A
  • Fertile days are calculated based upon the cycle length recorded over at least 6 cycles
  • First fertile day = shortest cycle minus 20
  • Last fertile day = longest cycle minus 10
166
Q

What is the temperature method?

A
  • Relies on increase in basal body temperature (0.2-0.4 degrees) due to a rise in progesterone following ovulation
  • Daily temperatures should be measured
  • Can be affected by infection, exercise and some medications
167
Q

What is the cervical mucus method?

A
  • Mucus on toilet tissue after wiping the vulva can be examined for consistency
  • Midcycle mucus due to rising oestradiol levels is clear, watery and slippery
  • Following ovulation, the mucus becomes thick and opaque due to progesterone
168
Q

What is cervical palpation and personal fertility monitoring?

A
  • Cervical Palpation
    • The cervix rises 1-2 cm midcycle
  • Personal Fertility Monitoring
    • Analyses disposable urine dipsticks to record the presence of metabolites of oestrogen and LH in the urine
169
Q

What is lactational amenorrhoea?

A
  • Low risk of breastfeeding when fully breastfeeding

- After 6 months, or if menses occur or breastfeeding is reduced, alternative contraception should be started

170
Q

Describe emergency contraception

A
  • Cu-IUD is the MOST EFFECTIVE method of emergency contraception and should ideally be offered as the first choice
  • It can be removed once pregnancy has been excluded or it can remain in place as a form of contraception
  • An emergency Cu-IUD can be inserted up to 5 days after unprotected sex or 5 days after predicted ovulation
  • NOTE: the blastocyst will implant between day 6-10 following fertilisation
  • Women should be encouraged to start an effective method of contraception immediately after EC to protect against future pregnancies
171
Q

What are two oral methods of emergency contraception?

A
  • Levonorgestrel (LNG 1.5 mg)
    • Effective up to 72 hours (3 days) after unprotected sex
  • Ulipristal acetate (30 mg)
    • Progesterone receptor modulator
    • Effective up to 120 hours (5 days) after unprotected sex
  • Both methods delay ovulation
  • Oral methods are much less effective than the Cu-IUD and prevents only 2/3 of pregnancies
172
Q

What length of birth to pregnancy intervals are associated with an increased risk of childhood mortality?

A
  • < 12 months

- Maternal and child deaths could be prevented if couples spaced their pregnancies more than 2 years apart

173
Q

What is the UK Abortion Law?

A
  • 1967 Abortion Act states that abortion can be performed if two registered medical practitioners acting in good faith agree that the pregnancy should be terminated on one of the recognised legal grounds
  • This does NOT apply to Northern Ireland
  • Most abortions are based on Ground C
174
Q

What are preabortion investigations?

A
  • Recommended
    • Gestation assessment (ultrasound or clinical)
    • Rhesus status (anti-D required if non-immunised RhD-negative)
  • Consider
    • STI testing
    • FBC (determine if anaemic)
175
Q

What is involved in a medical abortion?

A
  • This involves a combination of:
    • Mifepristone (progesterone receptor modulator)
    • Followed by misoprostol (prostaglandin analogue)
  • Progesterone is needed to maintain uterine quiescence
  • Administration of mifepristone brings about an increase in uterine contractility
  • It also sensitises the uterus to exogenous prostaglandins, so misoprostol can bring about expulsion
  • Effect of mifepristone is maximal at 48 hours
  • If misoprostol is administered at an interval of 24-48 hours later, then there is an increase in cramping pain, bleeding and expulsion of the foetus through the slightly dilated cervix
176
Q

What happens in the first 9 weeks of pregnancy regarding a medical abortion?

A
  • In the first 9 weeks of pregnancy, women safely administer these medications are home
  • Simple oral analgesia (e.g. ibuprofen) can be used for pain relief
  • At 9 weeks gestation, they will bleed for around 2 weeks following the medical abortion
177
Q

What happens after 9 weeks of pregnancy regarding a medical abortion?

A
  • The same drugs are used but requires repeated doses of misoprostol every 3 hours until expulsion occurs
  • Because of the discomfort, increased bleeding and passage of a larger foetus, this should be done in a clinical setting
  • In the 2nd trimester, average induction of abortion time is 7 hours
178
Q

What happens after 21 completed weeks?

A
  • Feticide should be used to eliminate the possibility of the aborted foetus displaying any signs of life
  • Usually achieved by intracardiac injection of potassium chloride or intrafoetal/intramniotic digoxin
179
Q

Describe a vacuum aspiration

A
  • Should be used to conduct surgical TOP up to 14 weeks
  • Involves gently dilating the cervix with gradual dilators then evacuating the cavity with gentle suction
  • Usually takes < 10 mins
  • Can be performed using manual vacuum aspiration or electrical vacuum aspiration
  • Can be performed under local or general anaesthesia
  • Consider pre-treatment of the cervix with misoprostol (causes cervical dilatation)
    • This should always be used after 12 weeks gestation or if nulliparous/adolescent/previous cervical surgery
    • Optimal regimen: 400 mcg misoprostol sublingually 1 hour before the surgical procedure
  • Prophylactic antibiotics reduce the risk of postabortal infection
180
Q

Describe dilatation and evacuation

A
  • After 14 weeks, this is the surgical intervention of choice
  • Needs good cervical dilatation (20 mm) to remove larger foetal parts
  • Achieved using:
    • Osmotic dilators
    • Misoprostol (vaginal or sublingual)
    • Mifepristone (oral)
  • At surgery, the cervix is further dilated and the contents of the uterus are removed using aspiration and extraction of the foetal tissue with appropriate instruments
  • Ultrasound is performed to confirm evacuation
181
Q

Describe sequelae of abortion

A
  • Both medical and surgical abortion have a low complication rate
  • Complications
    • Failure to end pregnancy
    • Incomplete abortion requiring evacuation
    • Infection
    • Haemorrhage
  • Without complications, there is NO impact on future reproductive potential
  • NO associated with future pregnancy or ectopic pregnancy
182
Q

What happens at the follow-up after abortion?

A
  • No medical need for follow-up after uncomplicated abortion
  • Provide good advice about when to seek help
  • Provide ongoing contraception
  • Women who have an early medical abortion at home, they should have a scheduled ultrasound to exclude ongoing pregnancy or a self-performed urine pregnancy test
183
Q

What is postabortal contraception?

A
  • Most women ovulate in the first month after abortion
  • Effective contraception should be started IMMEDIATELY
  • LARC has the best success rates at preventing unintended pregnancy
  • IUDs can be inserted at the time of surgical abortion
184
Q

What is subfertility?

A
  • Failure to conceive after 12 months of regular unprotected intercourse
  • Affects 1 in 7 heterosexual couples
  • Can be primary (couples that have never conceived together) or secondary (couples who have previously conceived together)
185
Q

What’s the chance of a healthy couple conceiving after having frequent intercourse in a single menstrual cycle?

A
  • 18-20%
186
Q

After 12 months, what percentage of couples should have conceived?

A
  • 80%
187
Q

What’s the most important factor affecting fertility age?

A
  • Female age

- Related to decline in quantity and quality of eggs

188
Q

When does female quality and sperm fertility decrease in quality?

A
  • Female fertility falls sharply at the age of 36 years

- Semen quality falls over the age of 50 years

189
Q

Describe natural conception

A
  • Having intercourse 3 x per week is associated with a 3 x increased risk of conceiving compared to couples having intercourse once per week
  • Maximum efficiency is probably achieved by having sex every other day
  • Increased frequency should be encouraged in the periovulatory stage
  • Eggs are fertilisable for about 12-24 hours after ovulation
  • Sperm can survive within the female reproductive tract for up to 72 hours
  • Ovulation usually occurs 14 days before menstruation
  • The fertile window will be different depending on the usual length of the cycle
  • NOTE: smoking can decrease quality and quantity of eggs and sperm
    • Extremes of BMI are also associated with reduced change of conceiving
    • Stress can affect the regulation of ovulation
  • IMPORTANT: all women intending to conceive should commence folic acid (400 mcg/day) to reduce risk of neural tube defects
190
Q

What are causes of female subfertility?

A
  • Ovulatory disorders
  • Tubal problems
  • Uterine disorders
  • Endometrial pathology
  • Endometriosis
  • General medical conditions (e.g. diabetes, epilepsy, thyroid problems)
191
Q

How do ovulatory disorders affect subfertility?

A
  • MOST COMMON causes of issues with ovulation is polycystic ovarian syndrome (PCOS)
  • Oligomenorrhoea in PCOS may require treatment, HOWEVER, the treatments may be incompatible with conceiving (e.g. COCP)
  • Hypothalamic disorders (e.g. hypothalamic hypogonadism) and pituitary disease (e.g. hyperprolactinaemia) are less common causes of anovulation
192
Q

How do tubal disorders affect subfertility?

A
  • Blockage is associated with inflammatory processes such as:
    • Pelvic Inflammatory Disease (PID)
      • Particularly chlamydia infection
  • Endometriosis
  • Previous pelvic or abdominal surgery (resulting in scar tissue and adhesions)
193
Q

How do uterine disorders affect subfertility?

A
  • Particularly, fibroids
  • Submucosal fibroids have an impact on embryo implantation
  • Intramural fibroids may reduce fertility if large
  • Subserosal fibroids have little impact
  • Endometrial polyps can reduce change of implantation
  • Endometrial scarring (Asherman’s syndrome) from surgery or infection can be associated with lighter periods and a significantly reduced chance of conception
194
Q

Describe male subfertility

A
  • Reduce sperm count and quality
  • Spermatogonial cells can be damaged by inflammation or damage to the epididymis (responsible for storing sperm)
  • Pelvic radiotherapy/surgery
  • Diabetes mellitus
  • Erectile difficulties/problems with ejaculation
  • Aneuploidy of sex chromosomes
195
Q

What are key points in a female subfertility history?

A
  • Age
  • Length of time spent trying for pregnancy
  • Any previous pregnancies
  • Coital frequency
  • Occupation
  • General gynaecological history
  • Previous history of pelvic inflammatory disease
  • Previous medical or surgical history
  • Previous fertility treatment
  • Cervical smear history
  • General health - screen for history of thyroid disorders

Examination
- Pelvic examination (watch out for pathology such as fibroids, adnexal masses or tenderness)

  • General blood pressure, pulse, height and weight
196
Q

What are key points in a male subfertility history?

A
  • Age
  • Length of time trying for pregnancy
  • Fathered any previous pregnancies
  • History of mumps or measles
  • History of testicular trauma, surgery to testis
  • Occupation
  • Medical and surgical history

Testicular examination
- Volume, consistency, masses, varicocoele, surgical scars

197
Q

When are investigations considered for subfertility?

A
  • Investigations may be considered in couples who have not conceived after 1 years of regular unprotected sex
  • Investigations are indicated more strongly if the couple have a history of predisposing factors (e.g. oligomenorrhoea, PID)
198
Q

What female investigations should be done for subfertility?

A
  • Blood hormone profile
    • Look at early follicular phase FSH, LH and oestradiol levels
    • Anti-Mullerian hormone (AMH) is helpful for assessing ovarian reserve
      • It is independent of the menstrual cycle
    • Mid-luteal progesterone should also be measured to confirm ovulation
  • If irregular menstrual cycle, TFTs, prolactin and testosterone may also be useful
  • Chlamydia testing
  • HIV, hepatitis B and hepatitis C screening if assisted reproductive technology (ART) is being considered
  • TVUSS
    • Assessment of pelvic anatomy
    • Antral follicle count (important parameter of ovarian reserve)
    • Identify pathology (e.g. hydrosalpinges, endometriotic cyst)
199
Q

What is measurement of ovarian reserve?

A
  • Female reproductive potential is directly proportionate to the remaining number of oocytes in the ovaries (ovarian reserve)
  • This declines after 35 years
  • This can be accelerated by genetic predisposition, surgery or following exposure to toxins
  • Ovarian reserve can help predict response to ovarian stimulation by ART
  • The antral follicle count (AFC) seen on TVUSS is a good indicator of ovarian reserve (
    • < 4 = poor response
    • 16+ = good response
  • Anti-Mullerian hormone is produced by granulosa cells and does NOT change in response to gonadotrophins so it is the most successful biomarker of ovarian reserve
  • Most clinics use both AMH and AFC to assess ovarian reserve
200
Q

Describe tubal assessment for subfertility

A
  • Usually assessed using hysterosalpingography (HSG) using X-ray or ultrasound
  • Tubal patency is not the same as tubal function
201
Q

What are male investigations for subfertility?

A
  • Main investigation is semen fluid analysis (SFA)
  • Looks at: volume, sperm concentration, total sperm number, motility, morphology, vitality and pH
  • Most places recommended 2-4 day abstinence from ejaculation before providing a semen sample
  • If initial SFA is abnormal, it should be repeated 3 months later (because sometimes SFA can be distorted by viral infection)
  • A hormone profile will be performed in men with a low sperm count or azoospermia (no sperm in the semen)
202
Q

What is the medical management of subfertility?

A
  • Ovulation induction- clomiphene or FSH
    • If anovulation (PCOS, idiopathic)
  • Intrauterine insemination (with or without stimulation with FSH)
    • Unexplained infertility
    • Anovulation unresponsive to OI
    • Mild male factor
    • Minimal to mild endometriosis
  • Donor insemination
    • Presence of azoospermia
    • Single women
    • Same sex couples
  • IVF
    • Patients with tubal pathology
    • Patients who underwent above treatments with no success
  • Donor egg with IVF
    • Women whose egg quality is poor
    • Previous surgery/chemotherapy where ovarian function was adversely affected
203
Q

What is the surgical management of subfertility?

A
  • Operative laparoscopy to treat disease and restore anatomy
    • Adhesions
    • Endometriosis
    • Ovarian cyst
  • Myomectomy - hysteroscopy, laparoscopy, laparotomy, fibroid embolisation
    • Fibroid uterus
  • Tubal surgery
    • Blocked Fallopian tubes amenable to repair
  • Laparoscopic ovarian drilling
    • PCOS unresponsive to medical treatment
  • Often used as an adjunct to ART (e.g. removal of hydrosalpinges is associated with a significant improvement in the success of IVF)
  • Usually a minimum access surgery (MAS) approach is taken
204
Q

What is ovarian induction?

A
  • This is the first line option for patients with PCOS ovulatory problems (provided tubal patency and normal semen analysis)
  • The most commonly used agent is clomiphene citrate (antioestrogen)
    • It binds to oestrogen receptors in the hypothalamus and pituitary thereby blocking the negative feedback exerted by oestrogen
    • This leads to a surge in gonadotrophin release
    • This stimulates the ovary to recruit more follicles for maturation
    • 70% of women on clomiphene will ovulate
    • 50% will of these women will become pregnant within 6 months
    • 12% risk of multiple pregnancy (requires ultrasound monitoring to track the growth of follicles and identify the time of ovulation to reduce the risk of multiple pregnancy)
  • Options in clomiphene-resistant women
    • Augmentation with metformin
    • Aromatase inhibitors
    • Injectable gonadotrophins
  • Ovarian induction can also be achieved by laparoscopic ovarian drilling (LOD) in PCOS
    • Only considered if unresponsive to clomiphene
  • If the anovulation is due to a hypothalamic issue, injectable gonadotrophins are more effective
205
Q

Describe intrauterine insemination

A
  • Performed by introducing a small sample of prepared sperm into the uterine cavity with a fine uterine catheter
    • May be useful in:
      • Mild endometriosis
      • Mild male factor
      • Couples who do not have intercourse
      • Single women
      • Same sex couples using donor sperm
  • 10-20% success rate per treatment cycle
  • May be preceded by several days of mild stimulation with SC injections of FSH
  • This aims to stimulate the ovaries to produce 2-3 mature follicles (this practice is called stimulated IUI)
  • Follicular tracking with ultrasound is essential to avoid over- or understimulation
  • Triggering ovulation and timing the insemination is achieved by a SC hCG injection
  • This mimics the endogenous LH surge
206
Q

Which causes of subfertility is IVF used for?

A
  • Tubal disease
  • Endometriosis
  • Failed ovulation induction
  • Failed IUI
  • Donor eggs
207
Q

How does the IVF process work?

A
  • Pituitary downregulation
    • The pituitary gland is down-regulated to prevent endogenous LH surges and premature ovulation
    • GnRH agonist is used to block FSH and LH release
    • Newer approaches using GnRH antagonists can shorten treatment time
  • Controlled Ovarian Stimulation
    • Achieved by daily SC doses of gonadotrophins
    • This causes multiple follicle recruitment
    • Close monitoring with TVUSS predicts the number of follicles and the timing of the egg collection
  • Inhibition of Premature Ovulation
    • The feedback from rising oestradiol levels due to follicular development should lead to an LH surge which causes ovulation
    • This is blocked in IVF to allow scheduling of egg collection
    • This is done using GnRH agonists or with newer GnRH antagonists
  • hCG trigger
    • hCG is a surrogate for the endogenous LH surge
    • It causes final maturation and enables egg collection
  • Egg Collection
    • Performed about 37 hours after hCG trigger
    • Under anaesthesia, a needle is inserted into the ovaries under TVUSS control, and follicular fluid is aspirated from each follicle that contains an oocyte
  • Fertilisation
    • Performed using prepared sperm
    • Usually involved insemination of around 100,000 sperm in a petri-dish with an egg
    • If the sperm are poor, individual sperm can be isolated and directly injected into the cytoplasm of the oocyte (intracytoplasmic sperm injection (ICSI))
    • Success rates:
      • IVF = 60%
      • ICSI = 70%
  • Embryo Culture
    • Incubated under strict conditions
    • May be transferred into the uterus after 2, 3 or 5 days after development
  • Embryo Transfer
    • Transferred into the uterus using a soft plastic catheter
    • The choice of how many to transfer depends on the couple (after medical/embryological advice)
    • Usually performed under transabdominal ultrasound guidance
  • Embryo cryopreservation
    • Spare embryos of good quality may be cryopreserved for future use
    • Same success rate as fresh embryos
  • Luteal Phase Support
    • Use of gonadotrophin agonists/antagonists to prevent premature LH surge leads to a reduction in the corpus luteum’s ability to produce progesterone
    • Patients are supplemented with progesterone following egg collection
    • Pregnancy test is performed 14 days after embryo transfer
  • Donor Gametes
    • Used when the male partner is azoospermic or in the case of single women or female same sex couples
    • IUI and IVF are both possible
    • Donor eggs may be used if the female has undergone early menopause or if other IVF treatments have been unsuccessful
  • Surgical Sperm Retrieval
    • If the sperm quality and quantity is low but they are present, ICSI is required to help achieve pregnancy
    • However, if azoospermic, surgical sperm retrieval may be required
    • The extracted sperm can be cryopreserved
  • Preimplantation Genetic Diagnosis
    • Couples who carry a genetic disease (but are fertile) may choose IVF and preimplantation genetic diagnosis to avoid an affected pregnancy
    • IVF creates multiple embryos and they can be genetically tested
    • Only embryos free of the disease will be transferred into the uterus
  • Success rates depend on the inheritance pattern of the disease
208
Q

How is fertility preserved?

A
  • Surgery, radiotherapy and chemotherapy may reduce reproductive potential
  • Men can bank sperm ahead of these treatments
  • Young women can go through IVF can freeze oocytes
209
Q

What is menopause?

A
  • Women’s final menstrual period. The accepted confirmation of this is made retrospectively after 1 year of amenorrhoea.
  • It is caused by the cessation of regular ovarian function
210
Q

What is perimenopause?

A
  • Time from the onset of ovarian dysfunction until 1 year after the last period (i.e. when the diagnosis of menopause is made)
    • Aka climacteric
211
Q

What is postmenopause?

A
  • All women who have been at least 1 year since their last period
212
Q

What is the median age of physical menopause?

A
  • 51 - 52
213
Q

What are the endocrine changes of physical menopause?

A
  • Menopause occurs when you run out of oocytes
  • Inhibin B is produced by the follicles within the ovary, so as the number of follicles declines, the production of inhibin B declines
  • In the perimenopausal years, small declines in inhibin drive an overall increase in pulsatility of GnRH secretion and overall FSH and LH levels
  • This results in an increased drive to the remaining follicles in an attempt to maintain follicle production and oestrogen levels
  • Decline in ovarian testosterone and other androgens as women age
    • NOTE: androgens come from ovaries, peripheral adipose tissue and adrenal glands
214
Q

How is physical menopause diagnosed?

A
  • Largely clinical
  • Symptoms
    • Menstrual irregularities/amenorrhoea
    • Oestrogen deficiency symptoms (e.g. hot flushes)
  • High FSH with low oestradiol may be suggestive of menopause (but can occur at certain points during a normal menstrual cycle)
  • In all women in whom a diagnosis of menopause is being considered, also consider the possibility of pregnancy
215
Q

What is premature ovarian insufficiency?

A
  • Menopause occurring before the age of 40 years
  • This is a distressing diagnosis, particularly if it happens before completion of her family
  • Gamete donation is the only option for young women who would like to conceive again
  • Women with POI may experience unpredictable ovarian activity leading to irregular vaginal bleeding and a small risk of pregnancy
  • All women with POI should be offered supportive care and counselling from a specialist unit
  • They should receive an individualised package of care
216
Q

What are the causes of premature ovarian insufficiency?

A
  • Primary
    • Chromosomal abnormalities (e.g. Turner’s syndrome, fragile X)
    • Autoimmune disease (e.g. hypothyroidism, Addison’s, myasthenia gravis)
    • Enzyme deficiencies (e.g. galactosaemia, 17a-hydroxylase deficiency)
  • Secondary
    • Chemotherapy or radiotherapy
    • Infections (e.g. TB, mumps, malaria, varicella)
217
Q

Describe medical treatments and menopause after cancer

A
  • Appropriate counselling before definitive irreversible treatment that may compromise fertility is important
  • GnRH agonists (e.g. buserelin, goserelin) can be used as treatments for endometriosis and other gynaecological issues but constant stimulation of GnRH receptors leads to desensitisation and reduces LH and FSH release
  • This can induce a temporary menopause
218
Q

What is surgical menopause?

A
  • May occur in the surgical management of fibroids, endometriosis and other gynaecological conditions
  • Bilateral salpingo-oophorectomy may be performed prophylactically in women at high risk of inherited malignancies (e.g. breast and ovarian cancer) with BRCA1/2 mutation screening
  • These women should be counselled so that they can choose the correct time for the procedure and counselling on how to manage the sudden hormone deficit
  • They will lose the effect of oestrogen and testosterone
219
Q

What are the vasomotor symptoms of menopause?

A
  • Some of the earliest changes during menopause
  • Colloquially referred to as hot flushes
  • Hot flushes occurring at night are called night sweats
  • Thought to be due to loss of the modulating effect of oestrogen on serotoninergic receptors within the thermoregulatory centre in the brain
  • This leads to exaggerated peripheral vasodilatory responses to slight changes in environmental temperature
  • Occur in up to 80% of women
  • Night sweats are particularly distressing as it can disturb sleep leading to exhaustion and impaired quality of life
  • Triggers include alcohol, caffeine and smoking
  • Symptoms tend to be worse in obese women
220
Q

What are the psychological symptoms of menopause?

A
  • Associated with low mood, lack of energy, tiredness and impaired quality of life
  • Consider the impact of external influences (e.g. relationships, previous history of depression)
221
Q

Describe cognitive function in menopause

A
  • Many women complain of some change in memory/global cognitive function
  • No change in onset or incidence of dementia
222
Q

How does the endometrium change during menopause?

A
  • Initial irregular or scanty vaginal bleeding is due to the reduction in oestrogenic endometrial stimulation with failing ovarian function (eventually resulting in secondary amenorrhoea)
  • Irregular heavy bleeding can occur due to episodic infrequent ovulation with fluctuations in oestrogen and unpredictable progesterone levels
223
Q

Describe Urogenital Tract and Vulvovaginal Atrophy in menopause

A
  • Vaginal dryness, irritation, burning, soreness and dyspareunia
  • Loss of oestrogenic support to the vaginal epithelium leads to reduced cellular turnover and reduced glandular activity
  • This means that the vaginal epithelium is less elastic and more easily traumatised
  • The urogenital system also becomes weaker as a barrier to infection
  • Thought to be due to increase in pH
  • Incidence of UTI increases (and the incidence of minor cystitis following sexual intercourse)
  • Small petechial haemorrhages may be seen on the surface of the vagina in severe cases
  • Older women may also have shrinkage and fusion of the labia with narrowing of the introitus
224
Q

Describe bone health in menopause

A
  • Bone density reaches a peak at 20-30 years
  • After this peak is reached, there is a steady decline in BMD until menopause
  • Then, bone loss is accelerated until the age of 60 years
  • Then there is further steady decline until death
225
Q

What is osteoporosis?

A
  • Osteoporosis: a skeletal disorder characterised by compromised bone strength predisposing to an increased fracture risk.
  • It is 4 x more common in women
226
Q

What are risk factors for osteoporosis?

A
  • Family history
  • Smoking
  • Alcoholism
  • Long-term steroid use
  • POI and hypogonadism
  • Medical treatment with induced menopause
  • Disorders of thyroid and parathyroid
  • Immobility
  • Disorders of gut absorption, malnutrition and liver disease
227
Q

How is the cardiovascular system affected by menopause?

A
  • Although outside the remit of a gynaecologist, they can identify and improve modifiable risk factors in patients
  • Change from a gynaecoid (breast and hip fat) to android (abdominal fat) pattern of fat distribution
  • Rise in triglycerides, total cholesterol and LDLs
  • Reduction in HDLs
  • Oestrogen has a supportive effect on the vessel wall favouring vasodilation and preventing atherogenesis
228
Q

What is the management of menopause?

A
  • The main aim is the prevention of long-term health problems
  • Diet and Lifestyle
  • Non-Hormonal Approaches
  • Alternative and Complementary Therapies
  • Non-Hormonal Prescription Treatments
  • HRT
229
Q

How do non-hormonal approaches manage menopause?

A
  • Many women will present after trying ‘natural’ methods
  • They should be informed that the beneficial effect of lifestyle measures should be checked before exploring appropriate non-hormonal measures
230
Q

How do alternative and complementary therapies manage menopause?

A
  • No evidence base
  • Potential for interactions with other pharmaceutical agents
  • Most of these are essentially weak HRT, so, if they are taking a high dose then they may be exposing themselves to the risks of HRT
231
Q

Describe non-hormonal prescription treatments for menopause

A
  • Alpha agonists
    • Clonidine
  • Beta-blockers
    • Propranolol
  • Modulators of central neurotransmission
    • Venlafaxine
    • Fluoxetine
    • Paroxetine
    • Citalopram
    • Gabapentin
  • May reduce symptoms of hot flushes
  • Other symptomatic treatments include:
    • Vaginal moisturisers
    • Lubricants
    • Osteoporosis treatments
      • Bisphosphonates
      • Raloxifene
      • Denosumab
      • Teriparatide
232
Q

What hormones are used in HRT?

A
  • Oestrogens
    • Oestadiol
    • Oestrone sulphate
    • Oestriol
    • Conjugated equine oestrogen
  • Progestogens
    • Norethisterone
    • Levonorgestrel
    • Dydrogesterone
    • Medroxyprogesterone acetate
    • Drospirenone
    • Micronised progesterone
233
Q

How is oestrogen used in HRT?

A
  • Oestrogen
    • If given WITHOUT progestogenic opposition there is a risk of endometrial hyperplasia and cancer
    • ONLY SUITABLE for women who no longer have a uterus because of hysterectomy
  • Oestrogen with progestogen
    • Administration of progestogen is necessary to protect the endometrium
    • Normally given cyclically in preparations over a 28-day cycle
      • 16-18 days = oestrogen ALONE
      • 10-12 days = oestrogen AND progesterone
      • This is called cyclical HRT
      • This results in monthly menstruation (suitable for perimenopause or early postmenopause)
    • Oestrogen and progesterone may also be given continuously (continuous combined HRT) to women who are:
      • Known to be post-menopausal
      • 54+ years
      • NOTE: about 90% will not experience any vaginal bleeding
  • There are a variety of progestogens that can be used - these may be switched to reduce side-effects
234
Q

How is testosterone used in HRT?

A
  • Used to be used for disorders of sexual desire and energy levels in women who failed to respond to normal HRT
235
Q

What are the two main routes of administration for HRT?

A
  • Oral
  • Transdermal
  • Oral is convenient and cheap but influences lipid metabolism and the coagulation system through its effect on the liver during first-pass metabolism
  • The transdermal route has the advantage of directly delivering the hormones to the systemic circulation, thereby avoiding the aforementioned adverse effects
  • Oestradiol and oestriol are also available as vaginal creams
  • Progestogen as levonorgestrel can be administered as an IUD
236
Q

What are the benefits of HRT?

A
  • Symptoms improved:
    • Vasomotor symptoms
    • Sleep patterns
    • Performance during the day
  • Prevention of osteoporosis
    • Increased BMD
    • Reduced incidence of fragility fractures
  • Lower genital tract
    • Dryness
    • Soreness
    • Dyspareunia
    • CVD (preventative if started early)
237
Q

What are absolute contraindications to HRT?

A
  • Suspected pregnancy
  • Breast cancer
  • Endometrial cancer
  • Active liver disease
  • Uncontrolled hypertension
  • Known current VTE
  • Known thrombophilia (e.g. factor V leiden)
  • Otosclerosis
238
Q

What are relative contraindications to HRT?

A
  • Uninvestigated abnormal bleeding
  • Large uterine fibroids
  • Past history of benign breast disease
  • Unconfirmed personal history or a strong family history of VTE
  • Chronic stable liver disease
  • Migraine with aura
239
Q

What are the side effects of HRT?

A

Side-Effects associated with Oestrogen

  • Breast tenderness/swelling
  • Nausea
  • Leg cramps
  • Headaches

Side-Effects associated with Progestogen

  • Fluid retention
  • Breast tenderness
  • Headaches
  • Mood swings
  • Depression
  • Acne
240
Q

What are the risks of HRT?

A
  • Cancer
    • HRT does not drastically increase breast cancer risk
    • There is no increase in mortality from breast cancer
    • HRT may promote growth of cancer cells rather than initiate them
    • Endometrial cancer and ovarian cancer are NOT significant risks of HRT use
    • Endometrial cancer risk is more or less eliminated if women are given progestogens
  • Cardiovascular disease and stroke
    • HRT in younger women is protective
    • HRT in older women may increase the risk of cardiovascular disease and stroke
      • This is a small effect - an additional 2 women per 10,000
  • Venous Thromboembolism
    • Similar effect to the OCP
    • Background incidence of VTE in women > 50 = 15-20 per 10,000
    • HRT doubles this risk
    • NOTE: transdermal HRT may not have as big an effect